BCL2L11 and neuroblastoma: In primary neuroblastoma tumors a similar heterogeneity in BIM binding partners was observed (42), suggesting that not all tumors will respond to navitoclax or venetoclax and that different specific inhibitors should be used in conjunction with MEK inhibitors.